减重干预对银屑病严重程度的影响:系统综述与Meta分析
结果显示减重干预(平均体重变化-6.7 kg)可显著降低PASI(MD -2.5)并改善DLQI(MD -5.0),PASI75达成率显著提高(RR 1.6),PASI50和PASI100无统计学显著效应但研究数少。
要点
- 减重干预可显著降低银屑病PASI评分(MD -2.5)。
- 减重干预显著提高PASI75达成率(RR 1.6)。
- 减重干预显著改善DLQI生活质量(MD -5.0)。
核心结论
- 减重干预可改善银屑病严重程度和生活质量,应考虑作为常规治疗的一部分。
主要发现
- 14项比较(n=1145,体重变化MD -6.7 kg)中,减重干预较对照显著降低PASI:MD -2.5(95%CI -3.8至-1.1,I2=85.2%)。
- 6项比较(n=681,体重变化MD -7.3 kg)中,减重干预显著提高PASI75达成率:RR 1.6(95%CI 1.1-2.2,I2=22.6%)。
- 4项比较(n=509,体重变化MD -4.0 kg)中,PASI50无统计学显著效应:RR 1.5(95%CI 0.9-2.4,I2=72.8%)。
- 2项比较(n=334,体重变化MD -5.2 kg)中,PASI100无统计学显著效应:RR 1.6(95%CI 0.3-9.7,I2=0.0%)。
- 7项比较(n=364,体重变化MD -7.8 kg)中,减重干预显著改善DLQI:MD -5.0(95%CI -9.7至-0.3,I2=96.0%)。
临床怎么用
- 可将减重干预纳入银屑病常规治疗,尤其对超重或肥胖患者。
局限性
- PASI50和PASI100分析纳入研究数少,结果受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriasis affects at least 60 million people worldwide, and 80% also live with overweight or obesity. Excess weight increases susceptibility to psoriasis and is associated with more severe disease. OBJECTIVES: To evaluate the impact of weight-loss interventions on psoriasis severity (Psoriasis Area and Severity Index [PASI], PASI50, PASI75, PASI100 [50%/75%/100% reduction in baseline PASI, respectively]) and quality of life (Dermatology Life Quality Index [DLQI]). METHODS: We systematically searched five databases and two trial registries (inception to 03/09/2025). Outcomes were informed by patient focus-group discussions. Randomized controlled trials (RCTs) in adults with psoriasis, comparing any weight-loss intervention versus usual care or a lower-intensity weight-loss intervention, were included. Studies had to report a change in weight and ≥1 psoriasis severity or quality-of-life measure. Random effects meta-analyses were used. RESULTS: Thirteen RCTs (1145 participants) with 14 comparisons were included. Eleven interventions advised dietary changes, of which four included physical activity. Three used weight-loss medications. Across 14 comparisons (n = 1145, mean difference (MD) in weight change: -6.7 kg), weight-loss interventions produced a greater reduction in PASI versus control: MD -2.5 (95%CI: -3.8 to -1.1, I2 = 85.2%). We found a significant effect of weight-loss interventions on the likelihood of achieving PASI75 (RR = 1.6, 95%CI: 1.1-2.2, I2 = 22.6% [based on six comparisons, n = 681, MD in weight change: -7.3 kg]). There was no statistically significant effect of the interventions on the likelihood of achieving PASI50 (RR = 1.5, 95%CI: 0.9-2.4, I2 = 72.8% [based on four comparisons, n = 509, MD in weight change: -4.0 kg]) or PASI100 (RR = 1.6, 95%CI: 0.3-9.7, I2 = 0.0% [based on two comparisons, n = 334, MD in weight change: -5.2 kg]), but both analyses were limited by few studies. Across seven comparisons (n = 364; MD in weight change -7.8 kg), weight-loss interventions were associated with a significant improvement in DLQI compared to control: MD -5.0 (95%CI: -9.7 to -0.3, I2 = 96.0%). CONCLUSIONS: High-certainty evidence suggests weight-loss interventions can improve psoriasis severity and quality of life, and should be considered as part of routine treatment.
引用
- Morrow S, Hawkins P, Griffiths CEM, et al. Impact of weight-loss interventions on psoriasis severity: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2025. PMID: 41416383. doi:10.1111/jdv.70247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。